A Phase 1 biodistribution study of p-boronophenylalanine [electronic resource].

Published: Washington, D.C. : United States. Dept. of Energy, 1991.
Oak Ridge, Tenn. : Distributed by the Office of Scientific and Technical Information, U.S. Dept. of Energy.
Physical Description: Pages: (12 pages) : digital, PDF file
Additional Creators: Brookhaven National Laboratory, United States. Department of Energy, United States. Department of Health and Human Services, and United States. Department of Energy. Office of Scientific and Technical Information

Access Online

www.osti.gov

Availability

Finding items...

Restrictions on Access

Free-to-read Unrestricted online access

Summary

The objectives of the Phase I BPA biodistribution study are as follows: Objective 1: To establish the safety of orally administered boronophenylalanine (BPA) as determined by monitoring of patient's vital signs and by clinical analysis of blood before and after BPA administration. Objective 2: To establish BPA pharmacokinetics by monitoring the rates of boron absorption into and clearance from the blood and the rate of urinary excretion of boron. Objective 3: To measure the amount of boron incorporated into human tumors (melanoma, glioma, and breast carcinoma) using samples obtained at surgery or biopsy. This report presents the results obtained from the first thirteen patients entered into the study. Three additional glioblastoma patients have been studied recently at Stony Brook, the tissues are still being analyzed.

Report Numbers

E 1.99:bnl-47079
E 1.99: conf-9110330--1
conf-9110330--1
bnl-47079

Subject(s)

Radiology And Nuclear Medicine

Other Subject(s)

Note

Published through SciTech Connect.
01/01/1991.
"bnl-47079"
" conf-9110330--1"
"DE92007606"
": CA42446"
Massachusetts Institute of Technology (MIT) workshop on neutron capture therapy, Cambridge, MA (United States), 31 Oct - 1 Nov 1991.
Coderre, J.A.

Funding Information

AC02-76CH00016

View MARC record | catkey: 14794877